Inferred Corneal Regeneration Program
Corneal Blindness/Disease (e.g., Fuchs' dystrophy, keratoconus)
Pre-clinicalActive
Key Facts
Indication
Corneal Blindness/Disease (e.g., Fuchs' dystrophy, keratoconus)
Phase
Pre-clinical
Status
Active
Company
About Cornea Biosciences
Cornea Biosciences is an early-stage biotech targeting the large and underserved market of corneal blindness and disease through regenerative medicine. Operating from the biotech hub of San Diego, the company is leveraging tissue engineering to create novel therapeutic and diagnostic solutions. As a private, pre-revenue entity likely in the pre-clinical or early clinical stage, its success will depend on advancing its platform, securing partnership funding, and demonstrating clinical proof-of-concept. The company faces typical development risks but operates in a space with clear regulatory pathways and high demand for alternatives to donor corneal transplants.
View full company profile